Log in

2186 Luye Pharma Group Ltd. HKEX · China

Luye Pharma Group (2186) news 2186 convertible notes and buyback news

Debt Financing ·

Luye Pharma to issue US$180,000,000 bonds due 2031

Luye Pharma plans US$180,000,000 of 5.25% convertible bonds due 2031 and a concurrent repurchase of its 6.25% convertible bonds due 2028 at US$1,031.25 per US$1,000 of principal. The announcement says the two transactions may or may not complete.

Latest Luye Pharma Group news

We have not published a story on Luye Pharma Group yet. When there is news, it will appear here.

Questions about Luye Pharma Group

Has Luye Pharma Group sold convertible notes?

Our latest story on this, dated Jun 4, 2026: "Luye Pharma to issue US$180,000,000 bonds due 2031". The story links the filing or release it is based on. Read the story.

Does Luye Pharma Group have a share buyback?

Our latest story on this, dated Jun 4, 2026: "Luye Pharma to issue US$180,000,000 bonds due 2031". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Luye Pharma Group?

Luye Pharma Group Ltd. trades under the ticker 2186 on HKEX.

Where is Luye Pharma Group listed?

Luye Pharma Group Ltd. is listed on HKEX. Our directory also records these other listings: GETTEX:LUP.

Which country or territory is Luye Pharma Group listed under?

Our directory records Luye Pharma Group Ltd. under China.

What does Luye Pharma Group do?

Our directory classifies Luye Pharma Group Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Luye Pharma Group?

The ISIN recorded for Luye Pharma Group Ltd. is BMG570071099.

Does aibio.space cover Luye Pharma Group?

aibio.space lists Luye Pharma Group Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

What is the latest Luye Pharma Group (2186) stock news?

Our latest story on Luye Pharma Group, dated Jun 4, 2026: "Luye Pharma to issue US$180,000,000 bonds due 2031". Luye Pharma plans US$180,000,000 of 5.25% convertible bonds due 2031 and a concurrent repurchase of its 6.25% convertible bonds due 2028 at US$1,031.25 per US$1,000 of principal. The announcement says the two transactions may or may not complete. Source.

Which companies are similar to Luye Pharma Group?

Companies in our directory listed in the same country and business area as Luye Pharma Group: Hunan Jiudian Pharmaceutical Co., Harbin Gloria Pharmaceuticals Co., Shanghai Henlius Biotech, Chengdu Easton Biopharmaceuticals Co., Jenkem Technology Co., Ginwa Enterprise (Group).

How can I follow Luye Pharma Group (2186) news?

Press Follow on this page to add Luye Pharma Group to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming Luye Pharma Group so far, in Debt Financing.

Investor discussion: Luye Pharma Group

Members talk about Luye Pharma Group (2186). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Luye Pharma Group, newest first. Each line links the filing it comes from.

  1. Listings

    Trading status: COMPLETION OF EARLY REDEMPTION OF OUTSTANDING US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028. Source

  2. Financings

    Share or debt issue: COMPLETION OF CONCURRENT REPURCHASE OF US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028. Source

  3. Financings

    Share or debt issue: COMPLETION OF ISSUE OF US$180,000,000 5.25 PER CENT. CONVERTIBLE BONDS DUE 2031. Source

  4. Financings

    Share or debt issue: OVERSEAS REGULATORY ANNOUNCEMENT. Source

  5. Financings

    Share or debt issue: (1) PROPOSED CONCURRENT REPURCHASE OF US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028; AND (2) PROPOSED ISSUE OF US$180,000,000 5.25 PER CENT. CONVERTIBLE BONDS DUE 2031. Source

  6. Financings

    Share or debt issue: (1) PROPOSED CONCURRENT REPURCHASE OF US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028; AND (2) PROPOSED ISSUE OF USD-DENOMINATED CONVERTIBLE BONDS. Source

  7. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE AND CONNECTED TRANSACTION CAPITAL INJECTION IN NANJING LUYE. Source

  8. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS AND CONNECTED TRANSACTION FURTHER ANNOUNCEMENT ON THE TRANSFER OF 25% INTEREST IN NANJING LUYE AND RELATED TRANSACTIONS - COMPLETION OF THE EQUITY TRANSFER. Source

  9. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS TRANSFER OF 25% INTEREST IN NANJING LUYE AND RELATED TRANSACTIONS. Source

  10. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION COMPLETION OF THE ISSUE OF EXCHANGEABLE PREFERENCE SHARES BY A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY. Source

  11. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION ISSUE OF EXCHANGEABLE PREFERENCE SHARES BY A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY. Source

  12. Financings

    Share or debt issue: OVERSEAS REGULATORY ANNOUNCEMENT. Source

  13. Financings

    Share or debt issue: OVERSEAS REGULATORY ANNOUNCEMENT. Source

  14. Financings

    Share or debt issue: OVERSEAS REGULATORY ANNOUNCEMENT. Source

  15. Financings

    Share or debt issue: OVERSEAS REGULATORY ANNOUNCEMENT. Source

  16. Financings

    Share or debt issue: OVERSEAS REGULATORY ANNOUNCEMENT. Source

  17. Financings

    Share or debt issue: OVERSEAS REGULATORY ANNOUNCEMENT. Source

  18. Financings

    Share or debt issue: COMPLETION OF THE ISSUE OF US$50,000,000 5.85 PER CENT. CONVERTIBLE BONDS DUE 2025. Source

  19. Financings

    Share or debt issue: OVERSEAS REGULATORY ANNOUNCEMENT. Source

Press releases

Headlines of Luye Pharma Group's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

  2. HKEXnews

    VOLUNTARY ANNOUNCEMENT MRNA VACCINE LY01620 FOR THE TREATMENT OF CERVICAL PRECANCEROUS LESIONS AND HPV-RELATED TUMORS TO ENTER INTO PHASE II CLINICAL TRIAL IN CHINA

  3. HKEXnews

    VOLUNTARY ANNOUNCEMENT SUCCESSFUL COMPLETION OF A U.S. BRIDGING CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03015 (VMAT2 INHIBITOR/SIGMA-1R AGONIST)

  4. HKEXnews

    COMPLETION OF EARLY REDEMPTION OF OUTSTANDING US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028

  5. HKEXnews

    POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2026

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT THE PHASE 2 CLINICAL TRIAL IN CHINA OF THE GROUP'S NEW DRUG LY03015 (A VMAT2 INHIBITOR/SIGMA-1R AGONIST) FOR THE TREATMENT OF TARDIVE DYSKINESIA HAS ACHIEVED POSITIVE RESULTS

  7. HKEXnews

    COMPLETION OF CONCURRENT REPURCHASE OF US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028

  8. HKEXnews

    COMPLETION OF ISSUE OF US$180,000,000 5.25 PER CENT. CONVERTIBLE BONDS DUE 2031

  9. HKEXnews

    OVERSEAS REGULATORY ANNOUNCEMENT

  10. HKEXnews

    (1) PROPOSED CONCURRENT REPURCHASE OF US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028; AND (2) PROPOSED ISSUE OF US$180,000,000 5.25 PER CENT. CONVERTIBLE BONDS DUE 2031

  11. HKEXnews

    (1) PROPOSED CONCURRENT REPURCHASE OF US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028; AND (2) PROPOSED ISSUE OF USD-DENOMINATED CONVERTIBLE BONDS

  12. HKEXnews

    NOTICE OF ANNUAL GENERAL MEETING

  13. HKEXnews

    VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE U.S. PK BRIDGING CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03015 (VMAT2 INHIBITOR/SIGMA-1R AGONIST)

  14. HKEXnews

    VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE CHINA PHASE II CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03017 FOR TREATING ALZHEIMER'S DISEASE-RELATED PSYCHOSIS

  15. HKEXnews

    VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE PHASE II CLINICAL TRIAL IN CHINA OF THE GROUP'S INNOVATIVE DRUG LY03020

  16. HKEXnews

    ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025

  17. HKEXnews

    DISCLOSEABLE AND CONNECTED TRANSACTION CAPITAL INJECTION IN NANJING LUYE

  18. HKEXnews

    DISCLOSEABLE TRANSACTIONS AND CONNECTED TRANSACTION FURTHER ANNOUNCEMENT ON THE TRANSFER OF 25% INTEREST IN NANJING LUYE AND RELATED TRANSACTIONS - COMPLETION OF THE EQUITY TRANSFER

  19. HKEXnews

    VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR CLASS 1 INNOVATIVE DRUG RUOXINLIN FOR THE NEW INDICATION OF GENERALIZED ANXIETY DISORDER ACCEPTED IN CHINA

  20. HKEXnews

    Terms of Reference for Nomination Committee of the board of directors of the Company

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2186 on TradingView.

Listing details

Luye Pharma Group Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2186, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Luye Pharma Group Ltd.
Ticker
2186
Listing
HKEX
Country or territory
China
Business scope
Pharmaceuticals: Major
ISIN
BMG570071099
Other listed symbols
GETTEX:LUP
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.